<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Incontinence, urinary; Duloxetine: urinary incontinence; Antimuscarinics: urinary tract; Oxybutynin; Tolterodine; Flavoxate; Darifenacin; Fesoterodine; Propiverine; Solifenacin; Trospium; Urinary: frequency; Urinary: incontinence; Propantheline: urinary tract; Antidepressants: tricyclic: urinary incontinence; Imipramine: urinary incontinence; Contigen" /><meta name="IX" content="Incontinence, urinary; Duloxetine: urinary incontinence; Antimuscarinics: urinary tract; Oxybutynin; Tolterodine; Flavoxate; Darifenacin; Fesoterodine; Propiverine; Solifenacin; Trospium; Urinary: frequency; Urinary: incontinence; Propantheline: urinary tract; Antidepressants: tricyclic: urinary incontinence; Imipramine: urinary incontinence; Contigen" /><title>Urinary incontinence: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5068-urinary-incontinence.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP5068-urinary-incontinence.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5068-urinary-incontinence.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP4758-obstetrics-gynaecology-and-urinary-tract-disorders.htm">7 Obstetrics, gynaecology, and urinary-tract disorders</a> &gt; <a href="PHP5031-drugs-for-genito-urinary-disorders.htm">7.4 Drugs for genito-urinary disorders</a> &gt; <a href="PHP5067-drugs-for-urinary-frequency-enuresis-and-incontinence.htm">7.4.2 Drugs for urinary frequency, enuresis, and incontinence</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP5067-drugs-for-urinary-frequency-enuresis-and-incontinence.htm" title="Previous: 7.4.2 Drugs for urinary frequency, enuresis, and incontinence">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP5075-darifenacin.htm" title="Next: DARIFENACIN">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Urinary incontinence</h1><?highlighter on?><div id="pC" class="jN"><div class="cL"><div class="cE"><h3 class="cO">Additional information</h3> <p class="cT"> interactions (<a href="bnf_int342-antimuscarinics.htm">Antimuscarinics</a>).</p></div></div><p>Incontinence in adults which arises from detrusor instability is managed by combining drug therapy with conservative methods for managing urge incontinence such as pelvic floor exercises and bladder training; stress incontinence is generally managed by non-drug methods. <strong>Duloxetine</strong>, an inhibitor of serotonin and noradrenaline re-uptake can be added and is licensed for the treatment of moderate to severe stress incontinence in women; it may be more effective when used as an adjunct to pelvic floor exercises.</p> <p>Antimuscarinic drugs reduce symptoms of urgency and urge incontinence and increase bladder capacity. <strong>Oxybutynin</strong> also has a direct relaxant effect on urinary smooth muscle. Side-effects limit the use of oxybutynin, but they may be reduced by starting at a lower dose. A modified-release preparation of oxybutynin is effective and has fewer side-effects; a transdermal patch is also available. The efficacy and side-effects of <strong>tolterodine</strong> are comparable to those of modified-release oxybutynin. <strong>Flavoxate</strong> has less marked side-effects but it is also less effective. <strong>Darifenacin</strong>, <strong>fesoterodine</strong>, <strong>propiverine</strong>, <strong>solifenacin</strong>, and <strong>trospium</strong> are newer antimuscarinic drugs licensed for urinary frequency, urgency, and incontinence. The need for continuing antimuscarinic drug therapy should be reviewed every 4–6 weeks until symptoms stabilise, and then every 6–12 months.</p> <p>The <a title="target-block: NICE and Scottish Medicines Consortium" href="PHP60-general-guidance.htm#PHP70"><em>Scottish Medicines Consortium</em></a> has advised (June 2008) that fesoterodine (<em>Toviaz</em>®) is accepted for restricted use within NHS Scotland as a second-line treatment for overactive bladder syndrome.</p> <p>Propantheline and tricyclic antidepressants were used for urge incontinence but they are little used now because of their side-effects. The use of imipramine is limited by its potential to cause cardiac side-effects.</p> <p>Purified bovine collagen implant (<em>Contigen</em>®, Bard) is indicated for <em>urinary incontinence</em> caused by intrinsic sphincter deficiency (poor or non-functioning bladder outlet mechanism). The implant should be inserted only by surgeons or physicians trained in the technique for injection of the implant.</p> <div id="PHP5070"><h2>Cautions</h2><p>Antimuscarinic drugs should be used with caution in the elderly (especially if frail), in those with autonomic neuropathy, and in those susceptible to angle-closure glaucoma. They should also be used with caution in hiatus hernia with reflux oesophagitis. Antimuscarinics can worsen hyperthyroidism, coronary artery disease, congestive heart failure, hypertension, prostatic hyperplasia, arrhythmias, and tachycardia. For <strong>interactions</strong>, see Appendix 1 (antimuscarinics).</p></div> <div id="PHP5073"><h2>Contra-indications</h2><p>Antimuscarinic drugs should be avoided in patients with myasthenia gravis, significant bladder outflow obstruction or urinary retention, severe ulcerative colitis, toxic megacolon, and in gastro-intestinal obstruction or intestinal atony.</p></div> <div id="PHP5074"><h2>Side-effects</h2><p>Side-effects of antimuscarinic drugs include dry mouth, gastro-intestinal disturbances including constipation, flatulence, taste disturbances, blurred vision, dry eyes, drowsiness, dizziness, fatigue, difficulty in micturition (less commonly urinary retention), palpitation, and skin reactions (including dry skin, rash, and photosensitivity); also headache, diarrhoea, angioedema, arrhythmias, and tachycardia. Central nervous system stimulation, such as restlessness, disorientation, hallucination, and convulsion may occur; children are at higher risk of these effects. Antimuscarinic drugs can reduce sweating, leading to heat sensations and fainting in hot environments or in patients with fever, and <em>very rarely</em> may precipitate angle-closure glaucoma.</p></div> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP5075-darifenacin"><a href="PHP5075-darifenacin.htm" title="DARIFENACIN">DARIFENACIN</a></li><li id="_PHP5077-duloxetine"><a href="PHP5077-duloxetine.htm" title="DULOXETINE">DULOXETINE</a></li><li id="_PHP5082-fesoterodine-fumarate"><a href="PHP5082-fesoterodine-fumarate.htm" title="FESOTERODINE FUMARATE">FESOTERODINE FUMARATE</a></li><li id="_PHP5084-flavoxate-hydrochloride"><a href="PHP5084-flavoxate-hydrochloride.htm" title="FLAVOXATE HYDROCHLORIDE">FLAVOXATE HYDROCHLORIDE</a></li><li id="_PHP5086-oxybutynin-hydrochloride"><a href="PHP5086-oxybutynin-hydrochloride.htm" title="OXYBUTYNIN HYDROCHLORIDE">OXYBUTYNIN HYDROCHLORIDE</a></li><li id="_PHP5094-propantheline-bromide"><a href="PHP5094-propantheline-bromide.htm" title="PROPANTHELINE BROMIDE">PROPANTHELINE BROMIDE</a></li><li id="_PHP5096-propiverine-hydrochloride"><a href="PHP5096-propiverine-hydrochloride.htm" title="PROPIVERINE HYDROCHLORIDE">PROPIVERINE HYDROCHLORIDE</a></li><li id="_PHP5100-solifenacin-succinate"><a href="PHP5100-solifenacin-succinate.htm" title="SOLIFENACIN SUCCINATE">SOLIFENACIN SUCCINATE</a></li><li id="_PHP5102-tolterodine-tartrate"><a href="PHP5102-tolterodine-tartrate.htm" title="TOLTERODINE TARTRATE">TOLTERODINE TARTRATE</a></li><li id="_PHP5106-trospium-chloride"><a href="PHP5106-trospium-chloride.htm" title="TROSPIUM CHLORIDE">TROSPIUM CHLORIDE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP5067-drugs-for-urinary-frequency-enuresis-and-incontinence.htm">Previous: 7.4.2 Drugs for urinary frequency, enuresis, and incontinence</a> | <a class="top" href="PHP5068-urinary-incontinence.htm#">Top</a> | <a accesskey="]" href="PHP5075-darifenacin.htm">Next: DARIFENACIN</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>